Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis (Q24242681)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis (English)

0 references

1 reference

3

Brian Feagan

0 references

author name string

Daniel C Baumgart

series ordinal

1

0 references

John K MacDonald

series ordinal

2

0 references

publication date

16 July 2008

0 references

published in

0 references

cites work

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Response of refractory colitis to intravenous or oral tacrolimus (FK506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Long-term tacrolimus: a promising therapeutic approach for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Tacrolimus in corticosteroid-resistant ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Inflammatory bowel disease: clinical aspects and established and evolving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Inflammatory bowel disease: cause and immunobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Guidelines for the management of inflammatory bowel disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Changes in extent of ulcerative colitis: a study on the course and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Calcineurin: form and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Therapeutic drug monitoring for immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Rescue therapy with tacrolimus in a patient with toxic megacolon.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Attenuation of epithelial injury in acute experimental colitis by immunomodulators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Course of ulcerative colitis: analysis of changes in disease activity over years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Composite liver--small bowel allografts with preservation of donor duodenum and hepatic biliary system in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Tacrolimus for active ulcerative colitis? Yes! (Even though Cochrane says "no")

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Oral tacrolimus treatment of severe colitis in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Characterization of Calcineurin in Human Neutrophils

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Oral Tacrolimus (FK 506) in Crohn's Disease Complicated by Fistulae of the Perineum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Tacrolimus (FK-506) treatment of fulminant colitis in a child

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Effects of FK506 on an experimental model of colitis in rats

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007216

7 January 2021